Literature DB >> 10698512

Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.

J Tsihlias1, W Zhang, N Bhattacharya, M Flanagan, L Klotz, J Slingerland.   

Abstract

The cell cycle is governed by cyclin dependent kinases (cdks), which are activated by binding of cyclins, inhibited by cdk inhibitors and regulated by phosphorylation and dephosphorylation. Exposure to high dose dihydrotestosterone (DHT) inhibits population growth of the human prostate carcinoma cell line, LNCaP. To determine the mechanism of growth arrest by high dose DHT, we assayed the changes in cell cycle profile and the cell cycle regulators that mediate these effects. Treatment of asynchronously growing LNCaP cells with 100 nM DHT caused a G1 arrest. The proportion of cells in S phase fell from 22 to 2%, while the G1 fraction rose from 74 to 92% by 24 h. Loss of phosphorylation of the retinoblastoma protein was noted and cdk4 and cyclin E/ cdk2 activities fell. Inhibition of these G1 cyclin dependent kinases was not due to loss of either cyclin or cdk proteins nor to increases in the cdk inhibitors p16INK4A and p21CiP1. p21Cip1 protein levels remained constant, and cyclin E-associated p21CiP1 fell, suggesting that p21CiP1 is not relevant to this form of cyclin E/cdk2 inhibition. Of note, total p27KiP1 levels and cyclin E-associated p27Kip1 increased as cells arrested and the amount of the CAK activated cdk2 bound to cyclin E decreased. p27KiP1 immunodepletion experiments demonstrated that the DHT-mediated increase in p27Kip1 was sufficient to fully saturate and inhibit target cyclin E/ cdk2. The inhibition of cyclin E/cdk2 by p27Kip1 contributes to G1 arrest of LNCaP following high dose DHT. p27KiP1 may be a key effector of androgen dependent growth modulation in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698512     DOI: 10.1038/sj.onc.1203369

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.

Authors:  Jingting Jiang; Yunqian Pan; Kevin M Regan; Changping Wu; Xueguang Zhang; Donald J Tindall; Haojie Huang
Journal:  Prostate       Date:  2011-05-31       Impact factor: 4.104

Review 2.  [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors:  P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

4.  Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.

Authors:  Anh Thu Bui; Meng-Er Huang; Maryline Havard; Fanny Laurent-Tchenio; François Dautry; Thierry Tchenio
Journal:  Cell Cycle       Date:  2017-04-20       Impact factor: 4.534

5.  Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.

Authors:  Shifeng Su; John T Minges; Gail Grossman; Amanda J Blackwelder; James L Mohler; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

6.  Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.

Authors:  Laura R Bohrer; Shuai Chen; Timothy C Hallstrom; Haojie Huang
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

Review 7.  Intermittent androgen suppression for prostate cancer.

Authors:  Nicholas C Buchan; S Larry Goldenberg
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

8.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

9.  An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells.

Authors:  Hongbo Wang; Daqian Sun; Peng Ji; James Mohler; Liang Zhu
Journal:  J Cell Sci       Date:  2008-07-15       Impact factor: 5.285

10.  The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.

Authors:  Salma Siddiqui; Stephen J Libertini; Christopher A Lucas; Alan P Lombard; Han Bit Baek; Rachel M Nakagawa; Kristine S Nishida; Thomas M Steele; Frank U Melgoza; Alexander D Borowsky; Blythe P Durbin-Johnson; LiHong Qi; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2020-04-21       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.